Saturday 17 October 2026
Export INDV’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
INDV Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
32.45
1.17
−3.48%
Follow INDV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.49 | 21.23 | 15.09 | 14.20 |
P/S ratio |
2.55 | 3.62 | 2.93 | 3.67 | |
P/FCF ratio |
25.76 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(77.28) | (20.29) | (419.95) | 21.32 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.45 | 3.72 | 3.19 | 3.89 | |
EV/EBITDA |
11.52 | 16.34 | 11.74 | 11.85 | |
EV/Operating CF |
16.33 | (170.70) | (37.11) | (129.41) | |
EV/FCF |
24.71 | (48.52) | (21.23) | (45.81) | |
Quick Ratio |
0.74 | 0.49 | 0.59 | 0.59 | |
Current Ratio |
0.96 | 0.71 | 0.86 | 0.84 | |
Net Debt/EBITDA |
(2.51) | 1.46 | 2.21 | 1.64 | |
Debt/Assets |
22.74% | 26.56% | 40.60% | 39.50% | |
Debt/Equity |
(1.56) | (3.26) | (3.37) | (2.34) | |
Asset Turnover |
0.82 | 0.98 | 1.00 | 0.99 | |
Operating CF/Net income |
(0.93) | (2.15) | (0.10) | 1.88 | |
Capex/Depreciation |
(4.00) | (4.80) | (5.00) | (2.33) | |
Interest Coverage |
3.67 | 13.33 | 19.57 | 79.50 | |
Research and Development Expense of Revenue |
10.51% | 5.88% | 5.05% | 3.50% | |
Selling, General and Administrative Expense of Revenue |
49.36% | 52.66% | 39.12% | 35.57% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.23% | 1.40% | 2.84% | 3.21% | |
Graham Net Nets |
(0.23) | (0.14) | (0.18) | (0.15) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
4.26% | 4.71% | 6.63% | 7.04% | |
Free Cash Flow Yield |
3.88% | (2.12%) | (5.13%) | (2.31%) | |
Revenue per Share |
2.51 | 2.86 | 2.56 | 2.88 | |
Operating CF per Share |
(0.31) | (1.77) | (0.07) | 1.92 | |
Capex per Share |
(0.16) | (0.19) | (0.16) | (0.06) | |
Free Cash Flow per Share |
(0.47) | (1.96) | (0.23) | 1.87 | |
Cash per Share |
3.56 | 1.56 | 1.41 | 1.87 | |
Shareholders Equity per Share |
(1.66) | (0.78) | (1.16) | (1.75) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.66) | (0.78) | (1.16) | (1.75) | |
Free Cash Flow |
(59.00) | (245.00) | (29.00) | 222.00 | |
Working Capital |
(43.00) | (262.00) | (112.00) | (143.00) | |
Capital Expenditures |
(20.00) | (24.00) | (20.00) | (7.00) | |
Net Current Asset Value |
(701.00) | (648.00) | (674.00) | (716.00) | |
EV/EBIT |
12.73 | 17.59 | 12.41 | 12.33 | |
Capex to Sales |
0.06 | 0.07 | 0.06 | 0.02 | |
Price to Operating Income |
13.28 | 17.12 | 11.38 | 11.63 | |
| Other line items | |||||
Average Receivables |
271.50 | 271.00 | 278.50 | 265.00 | |
Average Payables |
515.00 | 233.00 | 180.50 | 201.00 | |
Average Inventory |
166.50 | 160.00 | 157.50 | 149.50 | |
Average Assets |
1,440.00 | 1,258.50 | 1,286.00 | 1,342.50 | |
Average Common Equity |
(187.00) | (218.00) | (215.00) | (232.50) |
Columns are period end dates · fundamentals updated 2 Oct 2026